Bupropion: pharmacology and therapeutic applications. - Wikidata - awgldk - TriplyDB

Bupropion: pharmacology and therapeutic applications.

Bupropion: pharmacology and therapeutic applications.

http://www.wikidata.org/entity/Q34569990

about

Second-generation antidepressants for preventing seasonal affective disorder in adults Bupropion induced serotonin syndrome: a case report Reward-Induced Eating: Therapeutic Approaches to Addressing Food Cravings Psychostimulant treatment of cocaine dependence Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues Neuroimaging the Effectiveness of Substance Use Disorder Treatments.Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.The effects of opioids and opioid analogs on animal and human endocrine systems Bupropion decreases resting motor threshold: a case report.Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence Antidepressant-induced liver injury.Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature.Effect of bupropion treatment on brain activation induced by cigarette-related cues in smokers.Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment.Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts.Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.Stress, depression and cardiovascular dysregulation: a review of neurobiological mechanisms and the integration of research from preclinical disease models.Bupropion extended-release for depressive disorders.Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.Nicotinic receptors and stages of nicotine dependence.Classical neurotransmitters and neuropeptides involved in major depression: a review.Analgesic and anti-inflammatory activities of bupropion in animal models.Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's Wort.Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers.Sensitivity to change in cognitive performance and mood measures of energy and fatigue in response to morning caffeine alone or in combination with carbohydrate.Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis.Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy.Bupropion effects on high-fat diet-induced steatohepatitis and endothelial dysfunction in rats: role of tumour necrosis factor-alpha.Attention-Deficit/Hyperactivity Disorder.The effect of N-acetylcysteine or bupropion on methamphetamine self-administration and methamphetamine-triggered reinstatement of female rats.Effects of bupropion sustained release on task-related EEG alpha activity in smokers: Individual differences in drug response.

P2860

Q24187894-5E1C21D3-4F37-4F67-BA6A-6BD1711B918B Q24631553-3B3FD153-94FB-45EB-9B77-A89196398330 Q28074195-FE5B52B3-7A7E-47E2-922E-86A4DD89A48C Q28267550-C71C5BF9-CCEF-44EF-99CF-A3885FBA5CF8 Q30438802-24C86D94-E5CA-4B60-9DE5-2A6344632A37 Q31096451-AD372A54-8B7E-4C8E-9D1E-82840595BB41 Q33449522-E4336CF2-3C7E-4D66-8C01-85AF89B667FB Q33779667-1C7670FD-DC9B-4839-B273-A6BCDAEF7A18 Q34001632-23C16113-F6A9-415D-B4AB-365481A83B2B Q34164210-94C4846C-B282-407F-BBEB-8E2A4B56C9AC Q34580845-D23147D4-EA86-4E3C-919D-6B812B42032C Q35057288-9A2725EC-C938-4CFC-9944-21DBCD816A90 Q35545542-069ED219-6129-4079-B627-512BDC12472E Q36020455-F3A74A06-C9D2-4632-89D5-A7BB568B0E24 Q36406310-A015CCE5-3E4A-421E-A65D-65AC1D8D9C57 Q36828445-096A5834-520F-4162-A72D-3CD55E08E0E8 Q36885659-A5505C04-7424-4411-955B-FB79D6360445 Q36972675-8D8B68A5-02E4-441C-9B75-FBE94C0BE37F Q37035595-95BCD38D-8A17-4E61-BC86-EA1F6C2D4E33 Q37154793-4110B1B1-2BE8-41F9-BF59-582C92EF1E4F Q37226997-587EB469-DF36-4A0B-A6B4-594AE054CE10 Q37331171-370EA0E2-8894-4363-B6EC-38F2ED0758F7 Q37404292-C6452376-6221-4C28-9FFD-590B53187ADA Q37768172-DE471730-ADE3-4159-9FFA-EE520E881212 Q41859706-815B7AFA-A5EF-4AC0-A296-BADFAEDEDC06 Q42958186-99BC08F2-CFB9-49A2-A40D-E688E413ACC6 Q43183967-74F1642B-4284-4F89-B61B-AE9801ECA943 Q43239591-7FAE8F10-637D-428E-8F4F-1D1411B16069 Q47275311-AB7B415B-3C72-4533-BF82-6258150D5199 Q48027985-43F2169C-D194-4E03-AFFE-87EFA1D46D1D Q48044124-C0B24097-E56B-479C-8607-023E881B334B Q48362916-0844E0BE-F585-4A11-83C3-52EA0F051B89 Q51805679-0C24276C-39A4-45D6-B09A-77E3C42C2869 Q52616964-E8997617-C7D2-471C-8E72-FA61F6BA36E5 Q53666291-27D8A3E8-E90D-4399-9E0F-4FF702FF7AF2

P2860

Bupropion: pharmacology and therapeutic applications.

http://www.wikidata.org/entity/Q34569990

description

2006 nî lūn-bûn

@nan

2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Bupropion: pharmacology and therapeutic applications.

@ast

Bupropion: pharmacology and therapeutic applications.

@en

Bupropion: pharmacology and therapeutic applications.

@nl

type

label

Bupropion: pharmacology and therapeutic applications.

@ast

Bupropion: pharmacology and therapeutic applications.

@en

Bupropion: pharmacology and therapeutic applications.

@nl

prefLabel

Bupropion: pharmacology and therapeutic applications.

@ast

Bupropion: pharmacology and therapeutic applications.

@en

Bupropion: pharmacology and therapeutic applications.

@nl

P1433

Q34569990-3DD37961-64DF-4D85-9A61-3217A56250CE

P1476

Q34569990-ADDF62B8-DF03-43FB-9B2F-080B98A841BA

P2093

Q34569990-473442CD-F9A7-4C15-8EB4-669C9EA3A49B

Q34569990-6F098C84-E2A0-45A9-BCCF-8BC454383635

Q34569990-902AFF51-452D-42D2-B26B-217D93894B01

P2860

Q34569990-0183277B-F3BD-4144-9082-C3BBDC00C66B

Q34569990-02016A3C-5CE8-4E52-BC2A-E1DEECCECBA0

Q34569990-02153943-FCCE-44B9-8896-AE9D1B99CF54

Q34569990-02AA7171-5D56-4285-982F-116F004168C6

Q34569990-0618B5A4-7BAE-4AC3-A8AF-51E23AB9A5C7

Q34569990-0AFB349C-E07E-453F-8D97-4A6F5B5B6F7B

Q34569990-0BF291B0-FD76-4046-8FA2-963924956E36

Q34569990-1585AE84-0A27-4CF0-89C5-B9AFD44E977E

Q34569990-15EEAEB3-729B-44B7-B0F5-FAE4E3FD4CFE

Q34569990-1846C52A-6E07-4C5E-85B8-5A8B116EB20B

P304

Q34569990-6A8EB470-E221-42C1-A340-BDC1E3A51427

P31

Q34569990-C5138B39-DE72-4C03-A5F4-74F657054D85

P356

Q34569990-B6E8D429-1886-49E3-B27C-703C1715D848

P433

Q34569990-E94C9167-BBBD-4986-8618-0DA6DB775F12

P478

Q34569990-EDB2043D-31AC-45C8-BF2E-17025A20DA73

P577

Q34569990-4A59EBE5-A051-452C-9917-19DAE3157276

P5875

Q34569990-65777A3D-D01A-4D67-A4AA-735F7070651A

P698

Q34569990-42A59691-A3A3-4094-B549-4BE542AB3705

P921

Q34569990-52EE3B2C-AB68-4EA9-8AB5-DB1A5F83DBAA

P356

14737175.6.9.1249

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Bupropion: pharmacology and therapeutic applications.

@en

P2093

Kevin F Foley

http://www.w3.org/2001/XMLSchema#string

Kevin P DeSanty

http://www.w3.org/2001/XMLSchema#string

Richard E Kast

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines

Behavioral and biochemical investigations of bupropion metabolites

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

Binding of antidepressants to human brain receptors: focus on newer generation compounds

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters.

Nortriptyline toxicity secondary to interaction with bupropion sustained-release.

Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.

Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.

P304

1249-1265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737175.6.9.1249

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2006-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6784752

http://www.w3.org/2001/XMLSchema#string

P698

17009913

http://www.w3.org/2001/XMLSchema#string

P921